Levodropropizine
Star2
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Levodropropizine is a peripherally-acting antitussive agent.
- Generic Name
- Levodropropizine
- DrugBank Accession Number
- DB12472
- Background
Levodropropizine is under investigation in clinical trial NCT01573663 (A Drug-Drug Interaction Study of Ambroxol and Levodropropizine).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 236.315
Monoisotopic: 236.152477892 - Chemical Formula
- C13H20N2O2
- Synonyms
- levodropropizina
- Levodropropizine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Coughing •••••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image LEVOPRONT SYRUP 60 mg/10 ml Syrup 60 mg/10ml Oral EMERGING PHARMA (S) PTE LTD 1999-03-24 Not applicable Singapore - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DROPOLEV ŞURUP ,150 ML Levodropropizine (30 mg/5ml) + Chlorpheniramine maleate (2 mg/5ml) Syrup Oral BERKO İLAÇ VE KİMYA SAN. A.Ş. 2014-09-09 Not applicable Turkey PULMOTUS 30 MG+ 2 MG/5 ML ŞURUP, 150 ML Levodropropizine (30 mg/5mL) + Chlorpheniramine maleate (2 mg/5mL) Syrup Oral BERAT BERAN İLAÇ SAN. VE TİC. LTD. ŞTİ. 2019-09-10 Not applicable Turkey
Categories
- ATC Codes
- R05DB27 — Levodropropizine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazinanes
- Sub Class
- Piperazines
- Direct Parent
- Phenylpiperazines
- Alternative Parents
- N-arylpiperazines / Dialkylarylamines / Aniline and substituted anilines / N-alkylpiperazines / 1,3-aminoalcohols / Trialkylamines / Secondary alcohols / 1,2-diols / 1,2-aminoalcohols / Azacyclic compounds show 3 more
- Substituents
- 1,2-aminoalcohol / 1,2-diol / 1,3-aminoalcohol / Alcohol / Amine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Dialkylarylamine show 15 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- N-arylpiperazine, secondary alcohol, N-alkylpiperazine (CHEBI:82722)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3O31P6T4G3
- CAS number
- 99291-25-5
- InChI Key
- PTVWPYVOOKLBCG-ZDUSSCGKSA-N
- InChI
- InChI=1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1
- IUPAC Name
- (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol
- SMILES
- [H][C@@](O)(CO)CN1CCN(CC1)C1=CC=CC=C1
References
- General References
- AIFA Product Information: Salvituss (levodropropizine) for oral use [Link]
- External Links
- PubChem Compound
- 65859
- PubChem Substance
- 347828710
- ChemSpider
- 59270
- 52014
- ChEBI
- 82722
- ChEMBL
- CHEMBL1288810
- ZINC
- ZINC000019594545
- Wikipedia
- Levodropropizine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Acute Tracheobronchitis 1 somestatus stop reason just information to hide 3 Completed Treatment Cough 1 somestatus stop reason just information to hide 3 Completed Treatment Evaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic Bronchitis 1 somestatus stop reason just information to hide 2, 3 Recruiting Other Dyspnea 1 somestatus stop reason just information to hide 1 Completed Treatment Healthy Volunteers (HV) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral 0.6 g Solution Oral 60 mg Syrup Oral 30 mg/5ml Syrup Oral Syrup Oral 600 mg Syrup Oral 6 mg/mL Solution / drops Oral 60 MG/ML Tablet Oral 60 mg Syrup Oral 60 mg/5ml Solution Oral 0.06 g Syrup Oral 60 mg/10ml Syrup Oral 0.6 g Syrup Oral 60000000 mg Solution / drops Oral Syrup Oral Solution Oral Syrup Oral 0.6 mg Solution Oral 60.000 mg Syrup Oral 0.600 g Tablet Oral 60.000 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 97.1 mg/mL ALOGPS logP 0.63 ALOGPS logP 0.61 Chemaxon logS -0.39 ALOGPS pKa (Strongest Acidic) 14 Chemaxon pKa (Strongest Basic) 7.65 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 46.94 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 68.79 m3·mol-1 Chemaxon Polarizability 26.77 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-02di-6940000000-2c6f504ceae818e3ed7e Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-3411eeea47aa1faaee17 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0290000000-23aac6510a50f0f89473 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-01tl-4930000000-3cac032ee3deea5c1893 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-014r-0190000000-4136122f26318c05670e Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0n93-3920000000-3ede8eb0d08697e769fe Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9700000000-1a50ebc2d9b0bc1958a5 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 164.8452545 predictedDarkChem Lite v0.1.0 [M-H]- 151.35706 predictedDeepCCS 1.0 (2019) [M+H]+ 164.9686545 predictedDarkChem Lite v0.1.0 [M+H]+ 153.75261 predictedDeepCCS 1.0 (2019) [M+Na]+ 159.66515 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 22:31 / Updated at May 27, 2021 02:58